Search

Your search keyword '"Gee, Harriet"' showing total 176 results
Start Over Author "Gee, Harriet"
176 results on '"Gee, Harriet"'

8. Individualized Stereotactic Ablative Radiotherapy for Lung Tumors

Author

Gensheimer, Michael F., primary, Gee, Harriet, additional, Shirato, Hiroki, additional, Taguchi, Hiroshi, additional, Snyder, John M., additional, Chin, Alexander L., additional, Vitzthum, Lucas K., additional, Maxim, Peter G., additional, Wakelee, Heather A., additional, Neal, Joel, additional, Das, Millie, additional, Chang, Daniel T., additional, Kidd, Elizabeth, additional, Hancock, Steven L., additional, Shultz, David B., additional, Horst, Kathleen C., additional, Le, Quynh-Thu, additional, Wong, Samantha, additional, Brown, Eleanor, additional, Nguyen, Ngan, additional, Liang, Rachel, additional, Loo, Billy W., additional, and Diehn, Maximilian, additional

Published
2023
Full Text
View/download PDF

13. Stereotactic Ablative Body Radiotherapy for Early NSCLC: Changes in Pulmonary Function, Dyspnoea and Quality of Life

Author

Ahn, Julie, primary, Yeghiaian-Alvandi, Roland, additional, Hegi-Johnson, Fiona, additional, Browne, Lois H., additional, Graham, Peter Henry, additional, Chin, Yaw, additional, Gee, Harriet, additional, Vinod, Shalini, additional, Ludbrook, Jane, additional, Last, Andrew, additional, Dwyer, Patrick, additional, Ong, Anselm, additional, Aherne, Noel, additional, Azzi, Maria, additional, and Hau, Eric, additional

Published
2023
Full Text
View/download PDF

15. Tables S1-6 from miR-139-5p Modulates Radiotherapy Resistance in Breast Cancer by Repressing Multiple Gene Networks of DNA Repair and ROS Defense

Author

Pajic, Marina, primary, Froio, Danielle, primary, Daly, Sheridan, primary, Doculara, Louise, primary, Millar, Ewan, primary, Graham, Peter H., primary, Drury, Alison, primary, Steinmann, Angela, primary, de Bock, Charles E., primary, Boulghourjian, Alice, primary, Zaratzian, Anaiis, primary, Carroll, Susan, primary, Toohey, Joanne, primary, O’Toole, Sandra A., primary, Harris, Adrian L, primary, Buffa, Francesca M., primary, Gee, Harriet E., primary, Hollway, Georgina E., primary, and Molloy, Timothy J., primary

Published
2023
Full Text
View/download PDF

16. Figure S2 from miR-139-5p Modulates Radiotherapy Resistance in Breast Cancer by Repressing Multiple Gene Networks of DNA Repair and ROS Defense

Author

Pajic, Marina, primary, Froio, Danielle, primary, Daly, Sheridan, primary, Doculara, Louise, primary, Millar, Ewan, primary, Graham, Peter H., primary, Drury, Alison, primary, Steinmann, Angela, primary, de Bock, Charles E., primary, Boulghourjian, Alice, primary, Zaratzian, Anaiis, primary, Carroll, Susan, primary, Toohey, Joanne, primary, O’Toole, Sandra A., primary, Harris, Adrian L, primary, Buffa, Francesca M., primary, Gee, Harriet E., primary, Hollway, Georgina E., primary, and Molloy, Timothy J., primary

Published
2023
Full Text
View/download PDF

30. MicroRNA-Related DNA Repair/Cell-Cycle Genes Independently Associated With Relapse After Radiation Therapy for Early Breast Cancer

Author

Gee, Harriet E., Buffa, Francesca M., Harris, Adrian L., Toohey, Joanne M., Carroll, Susan L., Cooper, Caroline L., Beith, Jane, McNeil, Catriona, Carmalt, Hugh, Mak, Cindy, Warrier, Sanjay, Holliday, Anne, Selinger, Christina, Beckers, Rhiannon, Kennedy, Catherine, Graham, Peter, Swarbrick, Alexander, Millar, Ewan K.A., O'Toole, Sandra A., and Molloy, Timothy

Published
2015
Full Text
View/download PDF

36. Use of durvalumab in stage III non‐small‐cell lung cancer based on eligibility for the PACIFIC study.

Author

Boys, Emma, Gao, Bo, Hui, Rina, da Silva, Inês, Hau, Eric, Gee, Harriet, and Nagrial, Adnan

Subjects
THERAPEUTIC use of monoclonal antibodies, LUNG cancer, TERTIARY care, METASTASIS, CANCER relapse, TUMOR classification, TREATMENT effectiveness, CHEMORADIOTHERAPY, ELIGIBILITY (Social aspects), RESEARCH funding, PROGRESSION-free survival, DEATH, PROPORTIONAL hazards models, OVERALL survival
Abstract

Background: Durvalumab following concurrent chemoradiotherapy is standard treatment for unresectable stage III non‐small‐cell lung cancer based on the results of the PACIFIC trial. Based on trial criteria, not all patients are eligible for durvalumab in routine clinical practice. Methods: We evaluated eligibility for durvalumab in a real‐world clinical setting and the impact of eligibility on outcomes. Consecutive patients treated with concurrent chemoradiotherapy at two tertiary centers between January 2015 and June 2022 were assessed. Clinical characteristics and outcomes were evaluated based on eligibility criteria for the PACIFIC trial. Results: A total of 126 patients were included. Seventy patients (56%) were eligible for durvalumab. Ineligibility was associated with shorter progression‐free survival of 9.7 months versus 18.4 months (hazard ratio [HR] 0.61, 95% confidence interval [CI] 0.39–0.95, p = 0.029) and overall survival of 26.4 months versus 58.7 months (HR 0.47, 95% CI 0.28–0.80, p = 0.005). Common reasons for ineligibility were history of previous malignancy (32%) and progressive disease or death during chemoradiotherapy (25%). Ineligible patients who received durvalumab had similar outcomes to eligible patients who received durvalumab. Conclusions: In a real‐world cohort, adjuvant durvalumab is safe and beneficial in a substantial proportion of patients who would not have been eligible for the PACIFIC trial. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. EXTH-41. IMPROVING THE RADIOSENSITIVITY OF DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPG) BY TARGETING HYPOXIA AND MITOCHONDRIAL METABOLISM

Author

Shen, Han, primary, Chang, Cecilia, additional, Ing, Prunella, additional, Cook, Kristina, additional, McKelvey, Kelly, additional, Lai, Joey, additional, Gloss, Brian, additional, Prior, Victoria, additional, O'Neill, Geraldine, additional, Blackburn, Anneke, additional, Gee, Harriet, additional, and Hau, Eric, additional

Published
2021
Full Text
View/download PDF

40. Additional file 1 of Personal innovative approach in radiation therapy of lung cancer- functional lung avoidance SPECT-guided (ASPECT) radiation therapy: a study protocol for phase II randomised double-blind clinical trial

Author

Khalil, Azza Ahmed, Hau, Eric, Gebski, Val, Grau, Cai, Gee, Harriet, Nyeng, Tine Bisballe, West, Katrina, Kramer, Stine, Farlow, David, Knap, Marianne, Møller, Ditte Sloth, Hoffmann, Lone, and Farr, Katherina P.

Subjects
Data_FILES
Abstract

Additional file 1.

Published
2021
Full Text
View/download PDF

45. hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer

Author

Gee, Harriet E., Camps, Carme, Buffa, Franceca M., Patiar, Shalini, Winter, Stuart C., Betts, Guy, Homer, Jarrod, Corbridge, Rogan, Cox, Graham, West, Catherine M.L., Ragoussis, Jiannis, and Harris, Adrian L.

Subjects
Head and neck cancer -- Care and treatment, Head and neck cancer -- Patient outcomes, Head and neck cancer -- Research, Hypoxia -- Research, Biological markers -- Research, MicroRNA -- Analysis, Health
Published
2010

47. Circulating MicroRNAs as Prognostic Molecular Biomarkers in Human Head and Neck Cancer: A Systematic Review and Meta-Analysis

Author

Lamichhane, Shree Ram, Thachil, Thanuja, Gee, Harriet, and Milic, Natalie

Subjects
Article Subject
Abstract

Background. Circulating microRNAs (miRNAs) are potential molecular biomarkers for cancer detection; however, little is known about their prognostic role in head and neck cancer. This current study is aimed at evaluating the role of novel miRNAs in the survival of head and neck cancer patients. Materials and Methods. We performed a systematic literature search using online databases for articles published between December 2006 and February 2019. A meta-analysis was conducted to assess the correlation between miRNA expressions and overall survival (OS) among the selected head and neck cancer studies. After multilevel screening by reviewers, meta-analysis was performed using hazard ratios (HR) and associated 95% confidence interval (CI) of survival to calculate a pooled effect size. Result. A total of 1577 patients across 13 studies were included in the literature review, with 18 miRNAs upregulated and 4 miRNAs downregulated predicting a poor overall survival. The forest plot generated using cumulated survival data resulted in a pooled HR value of 2.943 (95% CI: 2.394-3.618) indicating a strong association of dysregulated miRNA expression with a poor outcome. Only 2 miRNAs—low levels of miR-9 and high levels of miR-483-5p—were observed in two studies, both showing a significant association with overall cancer survival. Conclusion. To our knowledge, this is the first comprehensive systematic review and meta-analysis that examines the prognostic role of circulating miRNAs from blood in head and neck cancer patients. The combined effect estimates a HR across multiple studies and also supports the previous individual findings that an alteration in miRNA expression is highly associated with poor prognosis. This has the potential to use serum and/or plasma miRNAs as biomarkers and become novel tools for predicting the prognosis of head and neck cancer patients in the near future.

Published
2019
Full Text
View/download PDF

48. Prognostic Role of MicroRNAs in Human Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Author

Lamichhane, Shree Ram, Thachil, Thanuja, De Ieso, Paolo, Gee, Harriet, Moss, Simon Andrew, and Milic, Natalie

Subjects
Article Subject
Abstract

Background. MicroRNAs (miRNAs) have been found to play an important role in the development and outcomes for multiple human cancers. Their role as a prognostic biomarker in non-small-cell lung cancer (NSCLC) remains unclear. This meta-analysis aims to clarify the role of various miRNAs in the survival of NSCLC patients. Materials and Methods. All studies were identified through medical database search engines. A meta-analysis was conducted to assess the correlation between miRNAs expressions and overall survival among those NSCLC studies. Relevant data were extracted from each eligible study regarding baseline characteristics and key statistics such as hazard ratio (HR), 95% confidence interval (CI), and P value, which were utilized to calculate a pooled effect size. Result. Thirty-two studies were included in the meta-analysis. Using a random effect model, the combined HR and 95% CI for overall survival (OS) was calculated as 1.59 (1.39–1.82), predicting a poor overall survival. Five miRNAs (miR-21, miR-155, miR-let-7, miR-148a, and miR-148b) were found to be of significance for predicting OS in at least two studies, hence, selected for subgroup analysis. Subgroup analysis disclosed that elevated levels of miR-21 and miR-155 in both cancer tissue and blood samples were associated with worse OS. Compared to American studies (I-squared

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results